Bausch (BHC) Down 5.4% Since Last Earnings Report: Can It Rebound?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • May 29, 2026

Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China

Thermage ® , a pioneer in non-invasive skin tightening,  was awarded the AAA Well-Known Trademark Certification, the highest recognition in China's domestic trademark evaluation system. LAVAL, QC, May 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aesthetics market, are proud to announce that their flagship brand, Thermage®, was awarded the prestigious AAA Well-Known Trademark Certification ("AAA") by the China Trademark Association (CTA), a renowned accreditation reserved for top-tier brands.

PRNewsWire • May 28, 2026

Bausch Health Companies Inc. (BHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Bausch Health Companies Inc. (BHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 20, 2026

Bausch Health Companies Inc. (BHC) Presents at Barclays 30th Annual Leveraged Finance Conference 2026 Transcript

Bausch Health Companies Inc. (BHC) Presents at Barclays 30th Annual Leveraged Finance Conference 2026 Transcript

Seeking Alpha • May 19, 2026

Bausch Health Announces 2026 Annual Meeting of Shareholder Results

LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders ("Annual Meeting") held on May 19, 2026, including Eiry W. Roberts, M.D.

PRNewsWire • May 19, 2026

Bausch + Lomb Launches PreserVision AREDS3™ Eye Vitamins in the United States

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of PreserVision AREDS3 eye vitamins, which combine the clinically proven AREDS2 nutrients recommended by the NEI to help reduce the risk of moderate-to-advanced AMD progression with a unique B-vitamin complex.* Built on decades of leadership in AREDS-based vitamins, PreserVision AREDS3 is the mos.

Business Wire • May 19, 2026

Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference

LAVAL, QC, May 13, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Thomas J. Appio, Chief Executive Officer, and Jean-Jacques Charhon, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the RBC Capital Markets 2026 Global Healthcare Conference in New York City on Wednesday, May 20, 2026.

PRNewsWire • May 13, 2026

Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference

LAVAL, QC, May 12, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that members of company management will participate in a fireside chat at the Barclays 30th Annual Leveraged Finance Conference in Austin, Texas on Tuesday, May 19, 2026. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's website.

PRNewsWire • May 12, 2026

Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the European launch of the Bi-Blade+ advanced dual-port vitrectomy cutter on the Stellaris Elite® Vision Enhancement System. “The launch of Bi-Blade+ is the latest example of our commitment to delivering meaningful innovation in Europe,” said Luc Bonnefoy, president, Surgical, Bausch + Lomb. “Stellaris Elite has.

Business Wire • May 7, 2026

Bausch Health: Strong Margins, Weak Volumes, Equity Story Hinges On Deleveraging

Bausch Health delivered a Q1 revenue and net profit beat, but organic growth remains weak and demand is stagnant. BHC's improved margins stem from reduced rebates and discounts, but underlying sales volumes declined, especially in key segments. The investment thesis hinges on deleveraging; if debt is reduced by 20-30%, shares could rise 15-30%, but risks remain high.

Seeking Alpha • May 7, 2026